OBJECTIVES: The impact of epidermal growth factor receptor (EGFR) status and the use of EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy have not been well discussed only in recurrent non-small-cell lung cancer (NSCLC). The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC in terms of the EGFR mutation status and the use of EGFR-TKI therapy.
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer † 
INTRODUCTION
Lung cancer continues to be the most frequently occurring type of cancer, with approximately 1.61 million new cases each year. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases [1] . Although surgery is the best therapeutic modality for patients with early stage NSCLC, recurrence is reported in 20-50% of all cases [2] [3] [4] [5] [6] [7] [8] [9] .
Treatment for recurrent disease is usually similar to that used for advanced disease; however, considering the diversity of recurrent disease and the postoperative state, there remains controversy regarding whether the standard treatment for advanced disease should be the standard treatment for recurrent disease. Chemotherapy and radiation therapy are commonly accepted treatment options for recurrent lung cancer, and several authors have described the effects of surgical resection in patients with recurrent disease [9] [10] [11] . On the other hand, no standard therapeutic policy for treating recurrent disease has been established. In addition, the post-recurrence survival of surgically treated NSCLC patients has been examined less often than the overall or diseasefree survival of patients with advanced disease.
Epidermal growth factor receptor (EGFR) is a receptor kinase that is highly expressed in cancer cells. Mutations in the EGFR gene that are frequently present in exons 18-21 have been reported to be critical gene mutations in the setting of NSCLC [12] [13] [14] . EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have been used to treat NSCLC, showing extremely good responses in some populations of NSCLC patients [15] [16] [17] . The development of these medicines has caused a major change in therapeutic strategies for treating advanced and recurrent disease. On the other hand, the impact of these medicines has not been well documented particularly for recurrent disease.
The purpose of this study was to identify the prognostic factors associated with post-recurrence survival after surgical resection of NSCLC and to examine the best therapeutic strategy for treating this disease based on the EGFR mutation status and the use of EGFR-TKI therapy.
MATERIALS AND METHODS

Patients
A total of 1237 consecutive patients who underwent surgical resection for NSCLC at the National Kyushu Cancer Center between January 2000 and December 2011 formed the initial study cohort. By the end of 2012, 280 patients from the cohort were identified as having recurrent disease.
Postoperative follow-up and diagnosis of recurrence. A follow-up examination was usually performed every 2-3 months for the first 2 years, then every 3-6 months thereafter. The routine follow-up procedures included a physical examination, haematological examination and chest radiography. In addition, chest and abdominal computed tomography was performed at least once a year. When recurrent disease was suspected, further examinations, such as brain magnetic resonance imaging, bone scintigraphy and fluorodeoxyglucose-positron emission tomography were added. Recurrent NSCLC was diagnosed based on physical examination results and diagnostic imaging findings of lesions consistent with recurrent disease. Differentiating between a second primary lung cancer and intrapulmonary metastasis was, in general, performed according to the definitions proposed by Martini and Melamed [18] . Histological confirmation of the diagnosis was obtained when clinically feasible. The date of recurrence was defined as the date of histological confirmation or, in cases diagnosed based on clinical evidence, the date of recognition of recurrent disease by the attending physician. Local recurrence was defined as disease recurrence at the surgical margin, ipsilateral hemithorax or mediastinum. Distant metastasis was defined as disease recurrence in the contralateral lung or outside of the hemithorax and mediastinum.
Data collection and extraction. Demographic, clinical and treatment data were abstracted from an institutional database that included all patients who had undergone thoracic surgery. The histological diagnosis of the tumours was made based on the criteria of the World Health Organization, [19] and the TNM Statistical analysis. Length of post-recurrence survival was measured from the date of initial recurrence to the date of death from any cause or date on which the patients was last known to be alive. The probability of survival was estimated using the Kaplan-Meier method. Differences in survival were evaluated by using log-rank test. Significant variables on post-recurrence survival under the univariate analysis were tested with a multivariate analysis using a Cox proportional hazards regression model. Statistical analyses were performed using JMP software package (SAS Institute, Inc). All P-values less than 0.05 were considered to be statistically significant.
RESULTS
Characteristics of the patients
The characteristics of the patients are summarized in Table 1 As the initial treatment for recurrence, chemotherapy was performed in 152 patients (54%), chemoradiotherapy was performed in 62 (22%), radiotherapy was performed in 32 (12%) and surgical resection was performed in 15 (5%) ( Table 3) . The remaining 19 patients (7%) received supportive care only. There were no significant differences among the patients according to the initial treatment strategy (Table 3) .
Survival analysis. The median post-recurrence survival time and 5-year survival rate of all patients were 25 months and 20.3%, respectively (Fig. 1) . The association between post-recurrence survival and the EGFR mutation status is shown in Fig. 2 . The median post-recurrence survival time was 44 months in the patients with an EGFR mutation-positive status, 21 months in the patients with a wild status and 15 months in the patients with an unknown status (P < 0.01) (Fig. 2A) . As to the adenocarcinoma cases, the median post-recurrence survival time was 44 months in the patients with an EGFR mutation-positive status, 21 months in the patients with a wild status and 20 months in the patients with an unknown status (P < 0.01) (Fig. 2B) . Among all cases, the median post-recurrence survival time according to the use of EGFR-TKI therapy was as follows: 49 months in the EGFR mutation-positive patients treated with EGFR-TKI therapy, 20 months in the EGFR wild or unknown patients treated with EGFR-TKI therapy and 17 months in the patients not treated with EGFR-TKI therapy (P < 0.01) (Fig. 3A) . With regard to the adenocarcinoma patients, the median post-recurrence survival time according to the EGFR-TKI therapy was 49, 23 and 20 months, respectively (P < 0.01) (Fig. 3B) . As to the EGFR mutationpositive cases, the median post-recurrence survival time was 49 months in the patients treated with EGFR-TKIs and 12 months in the patients without EGFR-TKIs. The patients treated with EGFR-TKIs exhibited significantly longer post-recurrence survival time than the patients treated without EGFR-TKIs (P < 0.01) (Fig. 4) .
A multivariate analysis identified the ECOG PS, brain metastasis, number of sites of recurrence and EGFR mutation status to be independent predictive factors for post-recurrence survival (P < 0.01, 0.01, 0.02 and <0.01, respectively) ( Table 4) .
DISCUSSION
In this study, we retrospectively investigated various aspects of the predictive factors for post-recurrence survival in resected NSCLC patients, particularly focusing on the EGFR mutation status and the use of EGFR-TKI therapy. Several studies have demonstrated predictive factors of post-recurrence survival in resected NSCLC patients [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Hung et al. and Sugimura et al. reported that the disease-free survival and treatment for the initial recurrence are prognostic predictors of post-recurrence survival [2, 9] . The site of recurrence and recurrent organs, such as extrathoracic regions, the liver, brain and so on, have also been reported to be predictive factors for post-recurrence survival [5, 6, 9] . Previous studies have demonstrated that local therapies such as radiotherapy and surgical resection succeed in improving the prognosis of selected patients with recurrent disease [9] [10] [11] 21] . When recurrence is diagnosed to be local, local therapy has been administrated based on indefinite standards at many facilities including our institution. In this study, some of the patients received local therapies, such as surgical resection, radiotherapy and chemoradiotherapy. The patients who received anticancer treatments for initial recurrence exhibited significantly better outcomes than those who received supportive care only. On the other hand, there were no significant differences in prognosis between the patients treated with these different local therapeutic modalities. The superiority of local therapy was not demonstrated in this study. Most previous studies of local therapy did not include the EGFR mutation status or the use of EGFR-TKI therapy in the analyses. Considering the efficacy of EGFR-TKI therapy for advanced or recurrent disease [15] [16] [17] , the presence of EGFR mutations should be included as a predictor of post-recurrence survival. In addition, the value of local therapy should be evaluated with due consideration of the EGFR mutation status and the use of EGFR-TKI therapy.
Recently, some studies reported a relationship between the EGFR mutation status, the use of EGFR-TKI therapy and postrecurrence survival in patients with recurrent NSCLC [6, 7] . Saisho et al. [6] reported EGFR mutations and the use of adjuvant chemotherapy to be prognostic factors. Similarly, Shimada et al. [7] reported that EGFR-TKI therapy prolongs post-recurrence survival in surgically resected NSCLC patients. On the other hand, these studies did not mention the details of the correlation between the EGFR mutation status and the use of EGFR-TKI therapy. In the present study, the EGFR mutation-positive patients exhibited significantly better outcomes than the other patients. In addition, similar results were observed in the adenocarcinoma cases. These results suggest that the EGFR mutation status should be identified when recurrence develops after surgery, especially in patients with adenocarcinoma. Our study also demonstrated that EGFR-TKI therapy promotes better outcome among patients with an EGFR mutation-positive status than among those with an EGFR wild or unknown status. Although it remains unclear how the EGFR mutation status impacts the prognosis of NSCLC [22, 23] EGFR mutationpositive patients obtain significant benefits from EGFR-TKI therapy. In this study, the median survival time of the patients with an EGFR mutation-positive status who received EGFR-TKI therapy was 49 months, and the patients exhibited much longer survival times than the patients with an EGFR wild or unknown status and those who did not receive EGFR-TKI therapy. On the other hand, not all patients received EGFR-TKI therapy as the initial therapy; some patients received EGFR-TKI therapy as second-or third-line treatment in this study. In addition, some patients received both gefitinib and erlotinib therapy. There are several limitations associated with this study. One limitation associated with this study is the retrospective study design. Although the indications and therapeutic strategies for recurrent disease were generally examined by the cancer board of our department, not all patients received treatment according to the same standard. Secondly, post-recurrence survival may be regulated not only by the initial therapy but also by second-or third-line therapy. Thirdly, the patients who received EGFR-TKI therapy included the patients who received gefitinib therapy, erlotinib therapy and both gefitinib and erlotinib therapy. Based on the number and variety of cases, we were unable to demonstrate the outcomes according to each drug. Despite these limitations, this study evaluated the influence of the EGFR mutation status and outcome of EGFR-TKI therapy in 280 recurrent NSCLC cases; therefore, these results reflect the actual clinical outcomes of recurrent NSCLC.
In conclusion, the EGFR mutation status, ECOG PS, brain metastasis and number of recurrent foci were found to be associated with post-recurrence survival in patients with NSCLC. The patients with an EGFR mutation-positive status received much greater survival benefits from EGFR-TKI therapy. In addition, patients may experience adverse effects if the EGFR mutation status is unknown; therefore, it is essential to identify the EGFR status in order to assess the therapeutic strategy for recurrent NSCLC.
